Pfizer
Pfizer’s biosimilar proves non-inferior to rituximab in lymphoma at ASH 2018
December 4, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ASH 2018, Pfizer, haemophilia
Joining the chorus of data presentations at the American Society of Hematology (ASH) Annual Meeting 2018, Pfizer has announced new …
Pfizer’s Daurismo becomes first of its kind to secure FDA approval in acute myeloid leukaemia
November 22, 2018Research and Development, Sales and Marketing AML, Daurismo, FDA, Pfizer, US, leukaemia
Pfizer has revealed that the FDA has chosen to approve its Daurismo (glasdegib) for the treatment of newly-diagnosed acute myeloid …
Pfizer ask Senator Cindy Hyde-Smith to refund campaign donation after ‘public hanging’ comments
November 21, 2018Research and Development Pfizer, cindy hyde smith, donations, politics, public hanging
American pharma giant Pfizer have asked Mississippi Republican Senator Cindy Hyde-Smith to return campaign donations after the candidate was filmed …
Merck KGaA and Pfizer’s Bavencio falls short in ovarian cancer
November 20, 2018Manufacturing and Production, Research and Development Bavencio, Cancer, Merck MGaA, Pfizer, ovarian cancer, pharma
Merck KGaA and Pfizer’s Bavencio (avelumab) has missed its primary endpoints in the treatment of platinum-resistant or -refractory ovarian cancer, …
Pfizer to resume price hiking in 2019; 41 drugs set to increase
November 20, 2018Manufacturing and Production, Sales and Marketing Pfizer, Trump, pharma, price hikes, price hiking, pricing
American pharma firm Pfizer has revealed plans to increase the prices of 41 medicines, the equivalent of 10% of its …
Pfizer defeated in Britain’s highest court over Lyrica patent
November 15, 2018Business Services, Medical Communications Legislation, Lyrica, Pfizer, court, pharma
American pharma firm Pfizer have lost in the final round of a protracted court battle over the patent on epilepsy …
Pfizer and Novartis partner up to develop combo therapies for NASH
October 29, 2018Research and Development, Sales and Marketing Novartis, Pfizer, liver, nash, pharma
Pfizer and Novartis are set to team up in a non-exclusive partnership aimed at the clinical development of one or …
Pfizer & Lilly’s non-opioid drug reduces pain in osteoarthritis
October 24, 2018Research and Development Eli Lilly, Pfizer, osteoarthritis, pharma
Pfizer and Eli Lilly have announced data revealing that their nerve growth factor (NGF) inhibitor tanezumab met all three of …
MSD’s Keytruda with Pfizer’s Inlyta beats Sutent in most common kidney cancer
October 19, 2018Medical Communications, Research and Development Cancer, Kidney cancer, MSD, Pfizer, inlyta, keytruda, pharma
MSD has unveiled new Phase 3 data on its blockbuster anti-PD-1 cancer therapy Keytruda (pembrolizumab) as part of a combination, …
Pfizer announce cull of 2% of staff
October 18, 2018Business Services, Medical Communications, Sales and Marketing Bourla, Ian Read, Jobs, Pfizer, america, layoffs
US pharma giant Pfizer is offering early retirement to American workers ahead of layoffs scheduled for next year. The company …
FDA approves Pfizer’s Talzenna for breast cancer alongside tool to identify eligible patients
October 17, 2018Research and Development, Sales and Marketing Cancer, FDA, Pfizer, Talzenna, breast cancer, pharma
Pfizer’s Talzenna (talazoparib) has secured FDA approval, it has emerged. The poly (ADP-ribose) polymerase (PARP) inhibitor is now set to …
NICE recommends Pfizer’s Mylotarg combo in CD33-positive acute myeloid leukaemia
October 8, 2018Sales and Marketing Mylotarg, NICE, Pfizer, acute myeloid leukaemia, leukaemia, pharma
NICE has revealed its recommendation for Pfizer’s Mylotarg (gemtuzumab ozogamicin) to be used on the NHS in the treatment of …
Ian Read steps down as Pfizer CEO
October 4, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CEO, Ian Read, Pfizer, pharma
Ian Read is set to step down from his position as Chief Executive Officer (CEO) of American pharma firm Pfizer, …
Pfizer CEO Ian Read set to step down from head position
October 1, 2018Manufacturing and Production, Sales and Marketing Albert Bourla, CEO, COO, Ian Read, Pfizer, Stock Markets
Ian Read is set to step down from his position as Chief Executive Officer (CEO) of American pharma firm Pfizer, …
Are biosimilars key to solving NHS access concerns?
October 1, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NHS, Pfizer, UK, biosimilars, celltrion, pharma
In light of continued austerity gripping the NHS, it was uplifting to hear in July that the health service had …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
